FHL-401

FHL-401 is a preclinical **peptide** therapeutic being developed by Forest Hills Business Association for synucleinopathies and related neurodegenerative disorders, including Alzheimer's Disease, Parkinson's Disease, Multiple System Atrophy, and Lewy Body Dementia. Available preclinical descriptions indicate that the peptide is designed to protect dopaminergic neurons by interfering with **Toll-like receptor 2 MyD88** signaling, thereby blocking the spread of synuclein-associated pathology and neuroinflammation. Reported preclinical effects also include neuronal protection, lysosomal biogenesis-mediated clearance of pathogenic molecules, and attenuation of brain inflammation, supporting its positioning as a potentially disease-modifying neurodegeneration program.